MGC PHARMACEUTICALS IN ACTION
Description: CannaTech Conference attended by MGC Pharmaceuticals in London, October 2017.
Description: Interview of Nitin Mantri, Senior Lecturer at RMIT University, as he discusses the first project of the collaboration between MGC Pharma and RMIT.
ABOUT MGC DERMA
MGC Derma is a leading cannabidiol (CBD) cosmetic brand with distribution deals signed across multiple markets and an aggressive growth plan to expand across multiple new markets.
The MGC Derma collection currently consists of 18 cannabidiol (CBD) based products that are available for purchase via exclusive distribution partners Cult Beauty and Harvey Nichols as well as directly on the MGC Derma online store.
H2 2018 will see the launch of a 1 more product across the Derma collections aimed at relieving the symptoms of inflammatory skin conditions such as psoriasis, eczema and acne.
LATEST DIVISIONAL NEWS
MGC Derma to be sold at Harvey Nichols – leading UK luxury retailer
MGC Derma’s CBD based cosmetics collection will be sold on the Ground Floor of the Beyond Beauty Department within Harvey Nichols flagship Knightsbridge store and online commencing 29 June 2018.
The MGC Derma and MGC Derma Plus collections, consisting of 18 products containing premium cannabidiol (CBD) are to be sold at Harvey Nichols from 29 June 2018. The products will be available to consumers in store and online internationally, where legally permitted. The premium range of MGC Derma products are research backed and independently tested – with 92% of participants stating would use the products on a daily basis2 . This positions the Division well under the luxury Harvey Nichols Brand.
ABOUT MGC BOTANIC
MGC’s Botanic Division engages with multiple cultivation sites to meet increasing global demand for high quality raw materials, alongside research into breeding and genetics with leading institutions and academia. MGC Botanic harvest product in Slovenia and Czech Republic, and use the raw material at MGC’s own production facility, as well as providing the product globally.
LATEST DIVISIONAL NEWS
Breeding and Cultivation Research Operations – Czech Republic
MGC Pharmaceuticals’ has recently completed harvest at our facility in the Czech Republic. The Company’s Panax operation progressed with over 450 medicinal cannabis plants entered the flowering phase after being transferred into the Company’s larger 1,100m2 glass house facility in June 2017. The growth and yield from the plants was better than expected for a first time crop in a new facility. Harvesting of the plants has produced over 400kg of high CBD and THC flowers. Working with the government’s Institute of Experimental Botany, the parameters of this cultivation cycle will be analysed to further optimise the Company’s growing protocols and maximise the yield of the medicinal cannabis strains.
Once harvested, biomass will be processed into CBD crystals for MGC Pharmaceuticals products including its MGC Derma cosmetics and for its clinical studies. The remaining biomass will be sold as Aquiol, a rich CBD >98% purity raw material.
Breeding and Cultivation Research Operations – Slovenia
The Botanic division’s collaboration with the University of Ljubljana is also progressing on schedule in Slovenia. Following the planting of medicinal cannabis seeds for its genetic research program in June 2017, the plants have now progressed to the flowering phase. The program aims to create genetic strains with high levels of cannabidiol (CBD) and new strains with high tetrahydrocannabinol (THC) levels for the treatment of specific disease symptoms. The team will now commence the first phase of the research project which focuses on the implementation and optimisation of molecular markers for sex determination and distinction between strains, as well as developing protocols for both.
Raw Material Production
The Company’s raw material production at its open field farm in Slovenia has also delivered encouraging production volumes. As planned, the Company has completed harvesting of its cannabis crops, yielding 4,000 kg of biomass in early October 2017. This biomass is now being dried and prepared for processing at MGC Pharmaceuticals European clean room and CO2 extraction facility where it will be turned into food grade cannabis. The CBD will be used for MGC Pharma’s nutrient and MGC Derma cosmetics products, with the remaining product being sold in the European market as Aquiol.
ABOUT THE MGC PHARMA DIVISION
MGC Pharma is focused on medical research and the development of the Company’s pharmaceutical products pipeline. The Pharma division holds unique IP which places the Company at the forefront of research and development for indications that will serve large global markets.
The Pharma division is focused on three specific areas of treatment:
- Neurological disorders, including proprietary formulations for Epilepsy;
- Oncological care and treatment; and
- Autoimmune diseases
LATEST DIVISIONAL NEWS
Maltese Government approves Medical Cannabis
Final legislation has been passed by the Maltese Parliament, legalising the production of cannabis for medical use in Malta.
This is a significant milestone for the Company which already has Malta Enterprise approval and a contract for a medicinal cannabis production facility. The Company is now expecting to have final formal agreements from the Malta Medicine Authority to be signed in the coming weeks.
Malta Enterprise, the government agency responsible for attracting Foreign Investment in Malta, has together with Malta Industrial Parks identified 4,000m2 of land for MXC. The planning has commenced for the construction of the MXC medical cannabis production and cultivation facility. Approval to immediately commence construction is expected to follow the receipt of MXC’s licence and final contracts from the Maltese authorities.
Click here to view the full announcement